Xu Lin


Xu Lin

 1.      Personal Information

Title/Position: Professor of Surgery
Vice president of the Affiliated Cancer Hospital of NJMU
Correspondence Address:  No. 42 Baiziting Road, Nanjing, China
Telephone: 02583283302
E-mail:  xulin83@vip.sina.com
2.      Education
(if applicable)
West China Medical University
Clinical Medicine
Shanghai Chest Hospital
Thoracic Surgery
Soochow University
Thoracic Surgery
University of Alberta, Canada
Visiting scholar
3. Research Interests
I am currently conducting research in several areas: (1) surgical treatment on central lung cancer, trachea and mediastinal tumor, (2) minimal invasive surgery of early stage lung cancer, (3) clinical research of comprehensive therapy of lung cancer, (4) basic research of molecular mechanisms of regulating lung cancer genesis and metastasis, and (5) basic research of lung injury protection.
4. Selected Publications
[1]   Wu Y, Lv J, Feng D, et al. Restoration of alveolar type II cell function contributes to simvastatin-induced attenuation of lung ischemia-reperfusion injury. Int J Mol Med. 2012. 30(6): 1294-306.
[2]   Qiu MT, Ding XX, Hu JW, Tian HY, Yin R, Xu L. Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials. Cancer Chemother Pharmacol. 2012 (online).
[3] Zhang LQ, Yin R, Li, Yang X, Jiang F, Xu L. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis. PLoS One 2013;8: e54970.
[4]   Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLOS ONE. 2012. 7(3): e34100.
[5]   Zhang Z, Huang J, Yin R, Xu L. A new technique for partial removal of the pulmonary artery in video-assisted thoracic surgical lobectomy. J Thorac Cardiovasc Surg. 2012. 144(2): 512-4.
[6]   Zhang LQ, Jiang F, Xu L, et al. The role of cyclin D1 expression and patient's survival in non-small-cell lung cancer: a systematic review with meta-analysis. Clin Lung Cancer. 2012. 13(3): 188-95.
[7] Jiang F, Xu L, Yuan F, Huang J, Lu X, Zhang Z. Carinal resection and reconstruction in surgical treatment of bronchogenic carcinoma with carinal involvement. J Thorac Oncol. 2009, 4(11): 1375-9. (Corresponding author)
[8] Jiang F, Xu L, Yuan FL, Huang JF, Lu XX. Lung autotransplantation technique in the treatment for central lung cancer of upper lobe. J Thorac Oncol. 2008, 3(6): 609-11. (Corresponding author)
[9] Jiang F, Yin R, Wang Z, Chen J, Yang M, Xu L. Transitory blocking of pulmonary artery and veins as a novel strategy in pulmonary surgery: an experimental study in a rabbit model. Eur Surg Res. 2010,44(3-4):125-32. (Corresponding author)
[1] Yin R, Xu L, Ren B, Jiang F, Fan X, Zhang Z, Li M, Hu Z. Clinical experience of lobectomy with pulmonary artery reconstruction for central non-small-cell lung cancer. Clin Lung Cancer. 2010,11(2):120-5. (Corresponding author)
[11] Yin R, Zhang Z, Jiang F, Feng D, Huang J, Xu L. Quick and effective technique for specimen extraction during video-assisted thoracic surgery. Thorac Cardiovasc Surg. 2010,8(4): 240-2. (Corresponding author)
[12] Ren B, Li M, Hu Z, Jiang F, Yin R, Zhang Z, Xu L. Establishment of a porcine model for lobar lung auto-transplantation. Transplant Proc. 2011,42(7): 2786-8. (Corresponding author)
[13] Jiang F, Yu MF, Ren B, Xu L. Nasogastric placement of sump tube turough the leak for the treatment of esophagogastric anastomotic leak after esophagectomy for esophageal carcinoma. Journal of surgical research. 2010,7(23):120-25. (Corresponding author)
[14] Hu Z, Yin R, X.Fan, Q.Zhang, Xu L,Treatment of intrathoracic anastomotic leak by nose fistula tube drainage after esophagectomy for cancer.Diseases of esophagus.2010,27(8):1-8. (Corresponding author)
[15] Li H, Zhang Q, Xu L,Chen Y,Wei Y, Zhou G. Factors predictive of prognosis for squamous cell cancer. The Journal of Thoracic and Cardiovascular Surgery. 2009,137(1):55-59.
[16] Li HH, Zhang QZ, Xu L, Hu JW. Clinical outcome of esophageal cancer after distal gastrectomy: a prospective study. Int J Surg. 2008,6(2):129-35.
[17] Yin R, Zhang S, Wu Y, Fan X, Jiang F, Zhang Z, Feng D, Guo X, XuL.microRNA-145 suppresses lung adenocarcinoma-initiating cell proliferation by targeting OCT4.Onco Rep. 2011,25(6):1747-54.(Corresponding author)
[18] Feng D, Zhang S, Hu Z, Fan F, Jiang F, Yin R, Xu L.Dynamic investigation of alveolar type II cell function in a long-term survival. Scand J Clin Lab Invest.2010 ,70(5):364-373. (Corresponding author)
[19] Dong J, Ren B, Hu Z, Chen J, Hu L, Dai J, Jin G, Xu L, Shen H. MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese. Mol Carcinog. 2011(Corresponding author)
[20] Xu L, Ren B, Li M, Jiang F, Zhang Z, Hu J. Ulinastatin suppresses systemic inflammatory response following lung ischemia-reperfusion injury in rats. Transplant Proc. 2008,40(5):1310-1.
[21] Chen S, Xu L, Tang J, Association of interleukin18 gene polymorphism with susceptibility to the development of acute lung injury afte cardiopulmonary by passsurgery. tissue antigens.2010,76:245–9. (Corresponding author)
[22] Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, et al.. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol. 2010. 28(10):1721-6.
[23] Tian T, Shu Y, Chen J, Hu Z, Xu L, Jin G, Liang J, Liu P, Zhou X, Miao R, Ma H.A functional genetic variant in microRNA-196a2 is associated with increased Cancer. Epidemiol Biomarkers Prev. 2009,18(4):1183-7.
[24] Jin G, Miao R, Hu Z, Xu L, Huang X, Chen Y, Tian T, Wei Q, Boffetta P, Shen H.Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese. Int J Cancer.2009,124(9):2172-8.
[25] Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L, Zeng Y, Miao R, Jin G, Ma H, Chen Y. Genetic variants of miRNA sequences and non-small cell lung cancer survival.J Clin Invest.2008,118(7):2600-8.
[26] Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y, Xu L, Wang X, Wei Q, Shen H.Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese.Int J Cancer.2006,118(5):1275-8.
[27] Hu Z, Shao M, Chen Y, Zhou J, Qian J, Xu L, Ma H, Wang X, Xu Y, Lu D, Shen H. Allele 2 of the interleukin-1 receptor antagonist gene (IL1RN*2) is associated.Cancer Lett.2006,236(2):269-75.
[28] Hu Z, Shao M, Yuan J, Xu L, et al.. Polymorphisms in DNA damage binding protein 2 (DDB2) and susceptibility of primary lung cancer in the Chinese: a case-control study. Carcinogenesis. 2006. 27(7): 1475-80.
[29] Hu Z, Xu L, Shao M, et al.. Polymorphisms in the two helicases ERCC2/XPD and ERCC3/XPB of the transcription factor IIH complex and risk of lung cancer: a case-control analysis in a Chinese population. Cancer Epidemiol Biomarkers Prev. 2006. 15(7): 1336-40.
[30] Ma H, Xu L, Yuan J, et al.. Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. Pharmacogenet Genomics. 2007. 17(6): 417-23.
[31] Jin G, Xu L, Shu Y, et al.. Common genetic variants on 5p15.33 contribute to risk of lung adenocarcinoma in a Chinese population. Carcinogenesis. 2009. 30(6): 987-90.
[32] Zhang M, Hu Z, Huang J, Shu Y, Dai J, Jin G, Tang R, Dong J, Chen Y, Xu L, et al.. A 3'-untranslated region polymorphism in IGF1 predicts survival of non-small cell lung cancer in a Chinese population. Clin Cancer Res. 2010. 16(4): 1236-44.
[33] Dong J, Dai J, Shu Y, Pan S, Xu L, et al. Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population. Carcinogenesis. 2010. 31(6): 1080-6.
[34] Jin G, Huang J, Hu Z, Dai J, Tang R, Chen Y, Xu L, et al. Genetic variants in one-carbon metabolism-related genes contribute to NSCLC prognosis in a Chinese population. Cancer. 2010. 116(24): 5700-9.
[35] Dai J, Jin G, Dong J, Chen Y, Xu L, Hu Z, Shen H, et al. Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival. J Thorac Oncol. 2010. 5(11): 1748-54.
[36] Hu Z, Shu Y, Chen Y, Chen J, Dong J, Liu Y, Pan S, Xu L, et al. Genetic Polymorphisms in the Precursor MicroRNA Flanking Region and Non-Small Cell Lung Cancer Survival. Am J Respir Crit Care Med. 2011. 183(5): 641-8.
[37] Dai J, Hu Z, Dong J, Xu L, et al. Host immune gene polymorphisms were associated with the prognosis of non-small-cell lung cancer in Chinese. Int J Cancer. 2011.
[38] Chu H, Cao W, Chen W, Pan S, Xiao Y, Liu Y, Gu H, Guo W, Xu L, Hu Z, Shen H. Potentially functional polymorphisms in IL-23R and risk of esophageal cancer in a Chinese population. Int J Cancer. 2011.
5. Scholarly and Professional Activities
Vice director of Lung Cancer Group and Thoracoscopy Surgery Group
Board member of Esophageal Cancer Group of Thoracic and Cardiovascular Surgery Branch of Chinese Medical Association
Standing director of the Chinese Anti-Cancer Association
Executive member of Chinese Society of Clinical Oncology (CSCO)
Vice director of the Cardiothoracic Surgery Branch of Jiangsu Medical Association
Senior editor of Chinese Journal of Oncology, Chinese Journal of Experimental Surgery, Chinese Journal of Thoracic and Cardiovascular Surgery, and Chinese Journal of Lung Cancer